Immunofoco's IMC002 Shows Promising Results at ASCO GI 2026: Durable Responses in Advanced Gastric Cancer Immunofoco unveiled encouraging results from its IMC002 therapy for advanced gastric cancer at ASCO GI 2026, highlighting a 66.7% response rate.

Immunofoco's IMC002 Shows Promising Results at ASCO GI 2026: Durable Responses in Advanced Gastric Cancer #China #Shanghai #CAR-T_therapy #Immunofoco #IMC002

Immunofoco: A Trailblazer in Solid Tumor Cell Therapy Recognized by Forbes Asia 100 to Watch 2025 Immunofoco has been named on the Forbes Asia 100 to Watch 2025 list for its groundbreaking developments in solid tumor cell therapies, marking a key achievement in biotech innovation.

Immunofoco: A Trailblazer in Solid Tumor Cell Therapy Recognized by Forbes Asia 100 to Watch 2025 #China #Shanghai #CAR-T_therapy #Biotech_Innovation #Immunofoco

Immunofoco Unveils Innovative CAR-T Technology at ASGCT 2025 Immunofoco presented groundbreaking CAR-T technology innovations at ASGCT 2025. Their platform promises enhanced efficacy in cancer treatment.

Immunofoco Unveils Innovative CAR-T Technology at ASGCT 2025 #China #Shanghai #CAR-T_Technology #Immunofoco #MxV-G